Teva and Lonza announce discontinuation of Biosimilar joint venture

Have you noticed recent changes to the Biosimilar partnership landscape with established partners deciding to part ways? As Biogeneric manufacturers adjust their development and access strategy based upon updates to the global regulatory landscape, strategic partners can become necessary and also irrelevant in an instant.

In October, the Business of Biosimilars will feature a strategic market overview of the Biosimilar partnerships landscape including trends and recent updates delivered by Giles Somers, Lead Analyst at Data Monitor. Giles heads up the Generics and Biosimilars team, and provides clients with concise strategic insight, as well as new analytical tools such as Biosimilar databases.

After the presentation, Giles will moderate a panel discussion on considerations that must be taken when embarking on a partnership featuring perspectives shared from David Shen at Teva, Carlos Bañado at mAbxience SA as well as others.

Want to learn more? Download our full agenda.

The 14th Annual Business of Biosimilars and Generic Drugs will take place October 15-17, 2012 in Boston, MA. As a reader of this blog, you’ll receive 15% off when you use code XP1886BLOG to register. Have any questions about the event? Feel free to contact Kate Devery at kdevery@iirusa.com or visit the webpage.

Cheers,
The Business of Biosimilars Team

Business of Biosimilars Webpage
Visit our Linkedin
Follow Us On Twitter

Share this article with your social network, just click below to share now!

Share |